01—Abstract
Summary
Summary of the 10-Q filed June 7, 2016. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported solid revenue growth for the three and six months ended April 30, 2016, with total net revenue increasing by 6%a and 3% respectively, year-over-year.
This growth was driven by strong performance across its business segments, particularly Agilent CrossLab and Diagnostics and Genomics, with Life Sciences and Applied Markets showing moderate improvement. The company demonstrated improved profitability, with gross margins increasing by 2 percentage points and operating margins by 2 and 3 percentage points for the three and six-month periods, respectively. This margin expansion was attributed to factors like exiting the NMR business, improved logistics, and a pension curtailment gain.
Financially, Agilent maintained a strong liquidity position with $2,139 millionb in cash and cash equivalents. The company continued to return capital to shareholders through dividends and share repurchases, demonstrating confidence in its ongoing cash flow generation.
Significant investments were made in acquisitions, including Seahorse Bioscience, and strategic equity investments, such as Lasergen, indicating a focus on future growth and innovation. Despite some unfavorable foreign currency impacts, the company expressed optimism for continued growth, focusing on operating margin expansion and strategic investments.
02—Key points
Key Highlights
- Total net revenue increased by 6% to $1,019 million for the three months ended April 30, 2016, and by 3% to $2,047 million for the six months ended April 30, 2016.
- Gross margin improved by 2 percentage points to 52.0% for the three months and by 2 percentage points to 52.1% for the six months ended April 30, 2016.
- Operating margin increased by 2 percentage points to 12.9% for the three months and by 3 percentage points to 14.0% for the six months ended April 30, 2016.
- Net income from continuing operations was $91 million for the three months and $214 million for the six months ended April 30, 2016.
- Cash flow from operations was strong, providing $360 million for the six months ended April 30, 2016.
- The company completed the acquisition of Seahorse Bioscience for $242 million and made a strategic investment in Lasergen for $80 million.
- Agilent returned capital to shareholders through $75 million in dividend payments and approximately $196 million in share repurchases during the six months ended April 30, 2016.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2016, Agilent Technologies, Inc. kept $0.09.
- Revenue$1.02B100.0%
- Cost of revenue−$489.0M48.0%
- Gross profit$530.0M52.0%
- Operating costs−$399.0M39.2%
- Operating income$131.0M12.9%
- Interest, other & tax−$40.0M3.9%
- Net income$91.0M8.9%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2016filed June 7, 2016Financial Statements
Q2 FY2016 against Q2 FY2015
| Line item | Q2 FY2016Q2 FY2015 | Change |
|---|---|---|
| Revenue | $1.02B$963.00M | +5.8% |
| Cost of Revenue | $489.00M$483.00M | +1.2% |
| Gross Profit | $530.00M$480.00M | +10.4% |
| R&D Expenses | $81.00M$81.00M | 0.0% |
| SG&A Expenses | $318.00M$292.00M | +8.9% |
| Operating Expenses | $888.00M$856.00M | +3.7% |
| Operating Income | $131.00M$107.00M | +22.4% |
| Interest Expense | $18.00M$17.00M | +5.9% |
| Net Income | $91.00M$87.00M | +4.6% |
| EPS (Basic) | $0.28$0.26 | +7.7% |
| EPS (Diluted) | $0.28$0.26 | +7.7% |
| Shares Outstanding (Basic) | 326.00M334.00M | −2.4% |
| Shares Outstanding (Diluted) | 328.00M337.00M | −2.7% |
05—Questions
Frequently Asked Questions
What was the overall revenue performance for Agilent Technologies in this quarter?
Agilent Technologies reported a 6% increase in total net revenue to $1,019 million for the three months ended April 30, 2016, compared to the same period last year. For the six months ended April 30, 2016, total net revenue increased by 3% to $2,047 million.
How did the company's profitability change?
Profitability improved significantly. Gross margins increased by 2 percentage points to 52.0% for the three-month period and to 52.1% for the six-month period. Operating margins also saw healthy increases, rising by 2 percentage points to 12.9% for the three-month period and by 3 percentage points to 14.0% for the six-month period.
What significant strategic investments or acquisitions did Agilent make during this period?
Agilent completed the acquisition of Seahorse Bioscience for $242 million in November 2015, the results of which were included in this quarter's financials. Additionally, they made a preferred stock investment of $80 million in Lasergen in March 2016.
How is Agilent managing its capital and returning value to shareholders?
Agilent demonstrated strong liquidity with $2,139 million in cash and cash equivalents as of April 30, 2016. The company continued its commitment to shareholder returns by paying $75 million in dividends and repurchasing approximately $196 million of its common stock during the six months ended April 30, 2016.
06—Continue